Effects of treatment with corticosteroids on human rhinovirus-induced asthma exacerbations in pediatric inpatients: a prospective observational study
Human rhinoviruses (HRVs) infection is a common cause of exacerbations in pediatric patients with asthma. However, the effects of corticosteroids on HRV-induced exacerbations in pediatric asthma are unknown. We conducted a prospective observational study to determine the viral pathogens in school-ag...
Saved in:
| Published in | BMC pulmonary medicine Vol. 23; no. 1; pp. 487 - 8 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
05.12.2023
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Human rhinoviruses (HRVs) infection is a common cause of exacerbations in pediatric patients with asthma. However, the effects of corticosteroids on HRV-induced exacerbations in pediatric asthma are unknown. We conducted a prospective observational study to determine the viral pathogens in school-age pediatric inpatients with asthma exacerbations. We assessed the effects of maintenance inhaled corticosteroids (ICS) on the detection rates of HRV species and treatment periods of systemic corticosteroids during exacerbations on pulmonary lung function after exacerbations.
Nasopharyngeal samples and clinical information were collected from 59 patients with asthma exacerbations between April 2018 and March 2020. Pulmonary function tests were carried out 3 months after exacerbations in 18 HRV-positive patients. Changes in forced expiratory volume in 1 second (FEV
)% predicted from baseline in a stable state were compared according to the treatment periods of systemic corticosteroids.
Fifty-four samples collected from hospitalized patients were analyzed, and viral pathogens were identified in 45 patients (83.3%) using multiplex PCR assay. HRV-A, -B, and -C were detected in 16 (29.6%), one (1.9%), and 16 (29.6%) patients, respectively. The detection rates of HRV-C were lower in the ICS-treated group compared with those in the ICS-untreated group (p = 0.01), whereas maintenance ICS treatment did not affect the detection rate for viral pathogens in total and HRV-A. Changes in FEV
% predicted in patients treated with systemic corticosteroids for 6-8 days (n = 10; median, 4.90%) were higher than those in patients treated for 3-5 days (n = 8; median, - 10.25%) (p = 0.0085).
Maintenance ICS reduced the detection rates of HRV (mainly HRV-C) in school-age inpatients with asthma exacerbations, and the treatment periods of systemic corticosteroids during exacerbations affected lung function after HRV-induced exacerbations. The protective effects of corticosteroids on virus-induced asthma exacerbations may be dependent upon the types of viral pathogen. |
|---|---|
| AbstractList | Human rhinoviruses (HRVs) infection is a common cause of exacerbations in pediatric patients with asthma. However, the effects of corticosteroids on HRV-induced exacerbations in pediatric asthma are unknown. We conducted a prospective observational study to determine the viral pathogens in school-age pediatric inpatients with asthma exacerbations. We assessed the effects of maintenance inhaled corticosteroids (ICS) on the detection rates of HRV species and treatment periods of systemic corticosteroids during exacerbations on pulmonary lung function after exacerbations.
Nasopharyngeal samples and clinical information were collected from 59 patients with asthma exacerbations between April 2018 and March 2020. Pulmonary function tests were carried out 3 months after exacerbations in 18 HRV-positive patients. Changes in forced expiratory volume in 1 second (FEV
)% predicted from baseline in a stable state were compared according to the treatment periods of systemic corticosteroids.
Fifty-four samples collected from hospitalized patients were analyzed, and viral pathogens were identified in 45 patients (83.3%) using multiplex PCR assay. HRV-A, -B, and -C were detected in 16 (29.6%), one (1.9%), and 16 (29.6%) patients, respectively. The detection rates of HRV-C were lower in the ICS-treated group compared with those in the ICS-untreated group (p = 0.01), whereas maintenance ICS treatment did not affect the detection rate for viral pathogens in total and HRV-A. Changes in FEV
% predicted in patients treated with systemic corticosteroids for 6-8 days (n = 10; median, 4.90%) were higher than those in patients treated for 3-5 days (n = 8; median, - 10.25%) (p = 0.0085).
Maintenance ICS reduced the detection rates of HRV (mainly HRV-C) in school-age inpatients with asthma exacerbations, and the treatment periods of systemic corticosteroids during exacerbations affected lung function after HRV-induced exacerbations. The protective effects of corticosteroids on virus-induced asthma exacerbations may be dependent upon the types of viral pathogen. Human rhinoviruses (HRVs) infection is a common cause of exacerbations in pediatric patients with asthma. However, the effects of corticosteroids on HRV-induced exacerbations in pediatric asthma are unknown. We conducted a prospective observational study to determine the viral pathogens in school-age pediatric inpatients with asthma exacerbations. We assessed the effects of maintenance inhaled corticosteroids (ICS) on the detection rates of HRV species and treatment periods of systemic corticosteroids during exacerbations on pulmonary lung function after exacerbations. Nasopharyngeal samples and clinical information were collected from 59 patients with asthma exacerbations between April 2018 and March 2020. Pulmonary function tests were carried out 3 months after exacerbations in 18 HRV-positive patients. Changes in forced expiratory volume in 1 second (FEV.sub.1)% predicted from baseline in a stable state were compared according to the treatment periods of systemic corticosteroids. Fifty-four samples collected from hospitalized patients were analyzed, and viral pathogens were identified in 45 patients (83.3%) using multiplex PCR assay. HRV-A, -B, and -C were detected in 16 (29.6%), one (1.9%), and 16 (29.6%) patients, respectively. The detection rates of HRV-C were lower in the ICS-treated group compared with those in the ICS-untreated group (p = 0.01), whereas maintenance ICS treatment did not affect the detection rate for viral pathogens in total and HRV-A. Changes in FEV.sub.1% predicted in patients treated with systemic corticosteroids for 6-8 days (n = 10; median, 4.90%) were higher than those in patients treated for 3-5 days (n = 8; median, - 10.25%) (p = 0.0085). Maintenance ICS reduced the detection rates of HRV (mainly HRV-C) in school-age inpatients with asthma exacerbations, and the treatment periods of systemic corticosteroids during exacerbations affected lung function after HRV-induced exacerbations. The protective effects of corticosteroids on virus-induced asthma exacerbations may be dependent upon the types of viral pathogen. BackgroundHuman rhinoviruses (HRVs) infection is a common cause of exacerbations in pediatric patients with asthma. However, the effects of corticosteroids on HRV-induced exacerbations in pediatric asthma are unknown. We conducted a prospective observational study to determine the viral pathogens in school-age pediatric inpatients with asthma exacerbations. We assessed the effects of maintenance inhaled corticosteroids (ICS) on the detection rates of HRV species and treatment periods of systemic corticosteroids during exacerbations on pulmonary lung function after exacerbations.MethodsNasopharyngeal samples and clinical information were collected from 59 patients with asthma exacerbations between April 2018 and March 2020. Pulmonary function tests were carried out 3 months after exacerbations in 18 HRV-positive patients. Changes in forced expiratory volume in 1 second (FEV1)% predicted from baseline in a stable state were compared according to the treatment periods of systemic corticosteroids.ResultsFifty-four samples collected from hospitalized patients were analyzed, and viral pathogens were identified in 45 patients (83.3%) using multiplex PCR assay. HRV-A, −B, and -C were detected in 16 (29.6%), one (1.9%), and 16 (29.6%) patients, respectively. The detection rates of HRV-C were lower in the ICS-treated group compared with those in the ICS-untreated group (p = 0.01), whereas maintenance ICS treatment did not affect the detection rate for viral pathogens in total and HRV-A. Changes in FEV1% predicted in patients treated with systemic corticosteroids for 6–8 days (n = 10; median, 4.90%) were higher than those in patients treated for 3–5 days (n = 8; median, − 10.25%) (p = 0.0085).ConclusionsMaintenance ICS reduced the detection rates of HRV (mainly HRV-C) in school-age inpatients with asthma exacerbations, and the treatment periods of systemic corticosteroids during exacerbations affected lung function after HRV-induced exacerbations. The protective effects of corticosteroids on virus-induced asthma exacerbations may be dependent upon the types of viral pathogen. Human rhinoviruses (HRVs) infection is a common cause of exacerbations in pediatric patients with asthma. However, the effects of corticosteroids on HRV-induced exacerbations in pediatric asthma are unknown. We conducted a prospective observational study to determine the viral pathogens in school-age pediatric inpatients with asthma exacerbations. We assessed the effects of maintenance inhaled corticosteroids (ICS) on the detection rates of HRV species and treatment periods of systemic corticosteroids during exacerbations on pulmonary lung function after exacerbations.BACKGROUNDHuman rhinoviruses (HRVs) infection is a common cause of exacerbations in pediatric patients with asthma. However, the effects of corticosteroids on HRV-induced exacerbations in pediatric asthma are unknown. We conducted a prospective observational study to determine the viral pathogens in school-age pediatric inpatients with asthma exacerbations. We assessed the effects of maintenance inhaled corticosteroids (ICS) on the detection rates of HRV species and treatment periods of systemic corticosteroids during exacerbations on pulmonary lung function after exacerbations.Nasopharyngeal samples and clinical information were collected from 59 patients with asthma exacerbations between April 2018 and March 2020. Pulmonary function tests were carried out 3 months after exacerbations in 18 HRV-positive patients. Changes in forced expiratory volume in 1 second (FEV1)% predicted from baseline in a stable state were compared according to the treatment periods of systemic corticosteroids.METHODSNasopharyngeal samples and clinical information were collected from 59 patients with asthma exacerbations between April 2018 and March 2020. Pulmonary function tests were carried out 3 months after exacerbations in 18 HRV-positive patients. Changes in forced expiratory volume in 1 second (FEV1)% predicted from baseline in a stable state were compared according to the treatment periods of systemic corticosteroids.Fifty-four samples collected from hospitalized patients were analyzed, and viral pathogens were identified in 45 patients (83.3%) using multiplex PCR assay. HRV-A, -B, and -C were detected in 16 (29.6%), one (1.9%), and 16 (29.6%) patients, respectively. The detection rates of HRV-C were lower in the ICS-treated group compared with those in the ICS-untreated group (p = 0.01), whereas maintenance ICS treatment did not affect the detection rate for viral pathogens in total and HRV-A. Changes in FEV1% predicted in patients treated with systemic corticosteroids for 6-8 days (n = 10; median, 4.90%) were higher than those in patients treated for 3-5 days (n = 8; median, - 10.25%) (p = 0.0085).RESULTSFifty-four samples collected from hospitalized patients were analyzed, and viral pathogens were identified in 45 patients (83.3%) using multiplex PCR assay. HRV-A, -B, and -C were detected in 16 (29.6%), one (1.9%), and 16 (29.6%) patients, respectively. The detection rates of HRV-C were lower in the ICS-treated group compared with those in the ICS-untreated group (p = 0.01), whereas maintenance ICS treatment did not affect the detection rate for viral pathogens in total and HRV-A. Changes in FEV1% predicted in patients treated with systemic corticosteroids for 6-8 days (n = 10; median, 4.90%) were higher than those in patients treated for 3-5 days (n = 8; median, - 10.25%) (p = 0.0085).Maintenance ICS reduced the detection rates of HRV (mainly HRV-C) in school-age inpatients with asthma exacerbations, and the treatment periods of systemic corticosteroids during exacerbations affected lung function after HRV-induced exacerbations. The protective effects of corticosteroids on virus-induced asthma exacerbations may be dependent upon the types of viral pathogen.CONCLUSIONSMaintenance ICS reduced the detection rates of HRV (mainly HRV-C) in school-age inpatients with asthma exacerbations, and the treatment periods of systemic corticosteroids during exacerbations affected lung function after HRV-induced exacerbations. The protective effects of corticosteroids on virus-induced asthma exacerbations may be dependent upon the types of viral pathogen. Background Human rhinoviruses (HRVs) infection is a common cause of exacerbations in pediatric patients with asthma. However, the effects of corticosteroids on HRV-induced exacerbations in pediatric asthma are unknown. We conducted a prospective observational study to determine the viral pathogens in school-age pediatric inpatients with asthma exacerbations. We assessed the effects of maintenance inhaled corticosteroids (ICS) on the detection rates of HRV species and treatment periods of systemic corticosteroids during exacerbations on pulmonary lung function after exacerbations. Methods Nasopharyngeal samples and clinical information were collected from 59 patients with asthma exacerbations between April 2018 and March 2020. Pulmonary function tests were carried out 3 months after exacerbations in 18 HRV-positive patients. Changes in forced expiratory volume in 1 second (FEV.sub.1)% predicted from baseline in a stable state were compared according to the treatment periods of systemic corticosteroids. Results Fifty-four samples collected from hospitalized patients were analyzed, and viral pathogens were identified in 45 patients (83.3%) using multiplex PCR assay. HRV-A, -B, and -C were detected in 16 (29.6%), one (1.9%), and 16 (29.6%) patients, respectively. The detection rates of HRV-C were lower in the ICS-treated group compared with those in the ICS-untreated group (p = 0.01), whereas maintenance ICS treatment did not affect the detection rate for viral pathogens in total and HRV-A. Changes in FEV.sub.1% predicted in patients treated with systemic corticosteroids for 6-8 days (n = 10; median, 4.90%) were higher than those in patients treated for 3-5 days (n = 8; median, - 10.25%) (p = 0.0085). Conclusions Maintenance ICS reduced the detection rates of HRV (mainly HRV-C) in school-age inpatients with asthma exacerbations, and the treatment periods of systemic corticosteroids during exacerbations affected lung function after HRV-induced exacerbations. The protective effects of corticosteroids on virus-induced asthma exacerbations may be dependent upon the types of viral pathogen. Keywords: Pediatric asthma, Corticosteroids, Exacerbation, Human rhinovirus Abstract Background Human rhinoviruses (HRVs) infection is a common cause of exacerbations in pediatric patients with asthma. However, the effects of corticosteroids on HRV-induced exacerbations in pediatric asthma are unknown. We conducted a prospective observational study to determine the viral pathogens in school-age pediatric inpatients with asthma exacerbations. We assessed the effects of maintenance inhaled corticosteroids (ICS) on the detection rates of HRV species and treatment periods of systemic corticosteroids during exacerbations on pulmonary lung function after exacerbations. Methods Nasopharyngeal samples and clinical information were collected from 59 patients with asthma exacerbations between April 2018 and March 2020. Pulmonary function tests were carried out 3 months after exacerbations in 18 HRV-positive patients. Changes in forced expiratory volume in 1 second (FEV1)% predicted from baseline in a stable state were compared according to the treatment periods of systemic corticosteroids. Results Fifty-four samples collected from hospitalized patients were analyzed, and viral pathogens were identified in 45 patients (83.3%) using multiplex PCR assay. HRV-A, −B, and -C were detected in 16 (29.6%), one (1.9%), and 16 (29.6%) patients, respectively. The detection rates of HRV-C were lower in the ICS-treated group compared with those in the ICS-untreated group (p = 0.01), whereas maintenance ICS treatment did not affect the detection rate for viral pathogens in total and HRV-A. Changes in FEV1% predicted in patients treated with systemic corticosteroids for 6–8 days (n = 10; median, 4.90%) were higher than those in patients treated for 3–5 days (n = 8; median, − 10.25%) (p = 0.0085). Conclusions Maintenance ICS reduced the detection rates of HRV (mainly HRV-C) in school-age inpatients with asthma exacerbations, and the treatment periods of systemic corticosteroids during exacerbations affected lung function after HRV-induced exacerbations. The protective effects of corticosteroids on virus-induced asthma exacerbations may be dependent upon the types of viral pathogen. |
| ArticleNumber | 487 |
| Audience | Academic |
| Author | Matsumoto, Koichiro Washio, Yasuyoshi Ninomiya, Takahito Oki, Takeshi Fujita, Masaki Fujimoto, Tsuguto Kan-o, Keiko Yoshida, Makoto Nakanishi, Yoichi |
| Author_xml | – sequence: 1 givenname: Keiko surname: Kan-o fullname: Kan-o, Keiko – sequence: 2 givenname: Yasuyoshi surname: Washio fullname: Washio, Yasuyoshi – sequence: 3 givenname: Takeshi surname: Oki fullname: Oki, Takeshi – sequence: 4 givenname: Tsuguto surname: Fujimoto fullname: Fujimoto, Tsuguto – sequence: 5 givenname: Takahito surname: Ninomiya fullname: Ninomiya, Takahito – sequence: 6 givenname: Makoto surname: Yoshida fullname: Yoshida, Makoto – sequence: 7 givenname: Masaki surname: Fujita fullname: Fujita, Masaki – sequence: 8 givenname: Yoichi surname: Nakanishi fullname: Nakanishi, Yoichi – sequence: 9 givenname: Koichiro surname: Matsumoto fullname: Matsumoto, Koichiro |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38053068$$D View this record in MEDLINE/PubMed |
| BookMark | eNptks9u1DAQhyNURP_AC3BAlrhwSbHjxHG4oKoqUKkSFzhbjjPedZXYwXa29EF4X2Z3S-kiFEVJJp8_azy_0-LIBw9F8ZrRc8akeJ9YJTta0orj3XayFM-KE1a3rKxqIY6evB8XpyndUspa2fAXxTGXtOFUyJPi15W1YHIiwZIcQecJfCZ3Lq-JCTE7E1KGGNyAhCfrZdKexLXzYePikkrnh8XAQHTK60kT-KkNxF5nF3wizpMZBqdzdAY_ZiyjPH0gmswxpBn3dRsgoU8QN7s1eiQpL8P9y-K51WOCVw_Ps-L7p6tvl1_Km6-fry8vbkrTsCaXBgTV3VDL2jDR9z0YAbQDpistqJG2ZgC674WsW04tr2xnjRWM9WxoBmhaflZc771D0Ldqjm7S8V4F7dSuEOJK6e0hjKDQPXRQdayxfV1TLQF64LbiDapqLdD1ce-al36CwWCrUY8H0sM_3q3VKmwUo6ITsqJoePdgiOHHAimrySUD46g9hCUpnLbsmla0DNG3_6C3YYl4fkh1tGJMCNn9pVYaO3DeBtzYbKXqom2bRnDOa6TO_0PhNcCE8_dgHdYPFrx52ulji39ShUC1BwyOOUWwjwijahtdtY-uwuiqXXSV4L8BZRPlTA |
| Cites_doi | 10.5694/j.1326-5377.2008.tb02046.x 10.1073/pnas.1421178112 10.1046/j.1365-2222.2000.00854.x 10.1002/jmv.20689 10.1056/NEJM200008033430504 10.1186/1465-9921-14-98 10.1038/ng.2830 10.1016/j.resinv.2020.06.006 10.1016/j.jaci.2017.08.003 10.1136/bmjopen-2018-028511 10.1038/srep07176 10.1164/rccm.201202-0330OC 10.1164/rccm.201303-0498OC 10.1186/s12931-017-0567-0 10.1016/j.resinv.2021.08.009 10.1183/09031936.00092410 10.1164/rccm.201705-1021OC 10.1093/infdis/jir634 10.1164/rccm.201904-0903SO 10.1016/S0954-6111(98)90305-5 10.3389/fmicb.2014.00226 10.1001/jamapediatrics.2019.0384 10.1086/339298 10.1371/journal.pone.0027898 10.1016/j.jaci.2004.09.025 10.1002/jmv.21819 10.1164/rccm.200807-1126OC 10.1378/chest.15-1335 10.1164/ajrccm.164.8.2104102 10.1016/j.alit.2020.02.005 10.1016/j.jaci.2004.11.014 10.1016/j.jaci.2016.09.028 10.1016/j.jaip.2021.03.035 10.1016/j.jpeds.2008.08.036 10.1164/rccm.201606-1213PP 10.1016/S0736-4679(97)00227-8 10.5414/CPP40256 10.1002/rmv.2193 |
| ContentType | Journal Article |
| Copyright | 2023. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
| Copyright_xml | – notice: 2023. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12890-023-02798-6 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2466 |
| EndPage | 8 |
| ExternalDocumentID | oai_doaj_org_article_ec6d9e2915fb440a8eebe3f2355de4a6 PMC10696820 A775563334 38053068 10_1186_s12890_023_02798_6 |
| Genre | Journal Article Observational Study |
| GeographicLocations | Japan United States--US |
| GeographicLocations_xml | – name: Japan – name: United States--US |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABUWG ACGFO ACGFS ACIHN ACPRK ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7TO 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c515t-ce60a9d484c16bbbec6e09e1a2a60c8f41eeabb684730f32f9fcf611b1d5de573 |
| IEDL.DBID | M48 |
| ISSN | 1471-2466 |
| IngestDate | Wed Aug 27 01:26:22 EDT 2025 Thu Aug 21 18:36:00 EDT 2025 Fri Jul 11 15:24:38 EDT 2025 Sat Jul 26 00:28:06 EDT 2025 Tue Jun 17 22:27:49 EDT 2025 Tue Jun 10 21:14:08 EDT 2025 Thu Jan 02 22:37:05 EST 2025 Tue Jul 01 02:40:34 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Exacerbation Pediatric asthma Corticosteroids Human rhinovirus |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c515t-ce60a9d484c16bbbec6e09e1a2a60c8f41eeabb684730f32f9fcf611b1d5de573 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2902116689?pq-origsite=%requestingapplication% |
| PMID | 38053068 |
| PQID | 2902116689 |
| PQPubID | 44785 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ec6d9e2915fb440a8eebe3f2355de4a6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10696820 proquest_miscellaneous_2898957671 proquest_journals_2902116689 gale_infotracmisc_A775563334 gale_infotracacademiconefile_A775563334 pubmed_primary_38053068 crossref_primary_10_1186_s12890_023_02798_6 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-12-05 |
| PublicationDateYYYYMMDD | 2023-12-05 |
| PublicationDate_xml | – month: 12 year: 2023 text: 2023-12-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC pulmonary medicine |
| PublicationTitleAlternate | BMC Pulm Med |
| PublicationYear | 2023 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | PM O'Byrne (2798_CR24) 2001; 164 KC Jamieson (2798_CR5) 2015; 148 AB Chang (2798_CR17) 2008; 189 2798_CR20 S Puranik (2798_CR3) 2017; 195 RS Karan (2798_CR35) 2002; 40 YA Bochkov (2798_CR29) 2015; 112 J Bizzintino (2798_CR8) 2011; 37 SJ Szefler (2798_CR12) 2005; 115 S Suissa (2798_CR23) 2000; 343 WM Lee (2798_CR7) 2012; 186 K Grunberg (2798_CR30) 2000; 30 JM Davies (2798_CR13) 2011; 6 S Langton Hewer (2798_CR33) 1998; 92 TF Griggs (2798_CR32) 2017; 18 H Arakawa (2798_CR19) 2020; 69 AM Fitzpatrick (2798_CR11) 2016; 138 T Saraya (2798_CR4) 2014; 5 T Jartti (2798_CR26) 2017; 140 BJ Thomas (2798_CR14) 2014; 4 ER Bleecker (2798_CR16) 2020; 201 H Ishiko (2798_CR22) 2002; 185 MK Iwane (2798_CR6) 2011; 204 YA Bochkov (2798_CR31) 2013; 14 MM van der Zalm (2798_CR37) 2009; 154 K Bonnelykke (2798_CR27) 2014; 46 RK Cydulka (2798_CR34) 1998; 16 R Normansell (2798_CR18) 2016; 5 PM O'Byrne (2798_CR1) 2009; 179 NW Johnston (2798_CR25) 2005; 115 K Bonnelykke (2798_CR28) 2018; 197 K Hasegawa (2798_CR9) 2019; 173 CS Murray (2798_CR15) 2021; 9 H Ortega (2798_CR2) 2021; 31 KE Arden (2798_CR38) 2006; 78 RM Fernandes (2798_CR39) 2019; 9 DW Cox (2798_CR10) 2013; 188 KE Arden (2798_CR36) 2010; 82 OK Kan (2798_CR21) 2022; 60 |
| References_xml | – volume: 189 start-page: 306 issue: 6 year: 2008 ident: 2798_CR17 publication-title: Med J Aust. doi: 10.5694/j.1326-5377.2008.tb02046.x – volume: 112 start-page: 5485 issue: 17 year: 2015 ident: 2798_CR29 publication-title: Proc Natl Acad Sci U S A. doi: 10.1073/pnas.1421178112 – volume: 30 start-page: 1015 issue: 7 year: 2000 ident: 2798_CR30 publication-title: Clin Exp Allergy. doi: 10.1046/j.1365-2222.2000.00854.x – volume: 78 start-page: 1232 issue: 9 year: 2006 ident: 2798_CR38 publication-title: J Med Virol. doi: 10.1002/jmv.20689 – volume: 343 start-page: 332 issue: 5 year: 2000 ident: 2798_CR23 publication-title: N Engl J Med. doi: 10.1056/NEJM200008033430504 – volume: 14 start-page: 98 year: 2013 ident: 2798_CR31 publication-title: Respir Res. doi: 10.1186/1465-9921-14-98 – volume: 46 start-page: 51 issue: 1 year: 2014 ident: 2798_CR27 publication-title: Nat Genet. doi: 10.1038/ng.2830 – ident: 2798_CR20 doi: 10.1016/j.resinv.2020.06.006 – volume: 140 start-page: 895 issue: 4 year: 2017 ident: 2798_CR26 publication-title: J Allergy Clin Immunol. doi: 10.1016/j.jaci.2017.08.003 – volume: 9 start-page: e028511 issue: 8 year: 2019 ident: 2798_CR39 publication-title: BMJ Open. doi: 10.1136/bmjopen-2018-028511 – volume: 4 start-page: 7176 year: 2014 ident: 2798_CR14 publication-title: Sci Rep. doi: 10.1038/srep07176 – volume: 186 start-page: 886 issue: 9 year: 2012 ident: 2798_CR7 publication-title: Am J Respir Crit Care Med. doi: 10.1164/rccm.201202-0330OC – volume: 188 start-page: 1358 issue: 11 year: 2013 ident: 2798_CR10 publication-title: Am J Respir Crit Care Med. doi: 10.1164/rccm.201303-0498OC – volume: 18 start-page: 84 issue: 1 year: 2017 ident: 2798_CR32 publication-title: Respir Res. doi: 10.1186/s12931-017-0567-0 – volume: 60 start-page: 129 issue: 1 year: 2022 ident: 2798_CR21 publication-title: Respir Investig. doi: 10.1016/j.resinv.2021.08.009 – volume: 37 start-page: 1037 issue: 5 year: 2011 ident: 2798_CR8 publication-title: Eur Respir J. doi: 10.1183/09031936.00092410 – volume: 197 start-page: 589 issue: 5 year: 2018 ident: 2798_CR28 publication-title: Am J Respir Crit Care Med. doi: 10.1164/rccm.201705-1021OC – volume: 204 start-page: 1702 issue: 11 year: 2011 ident: 2798_CR6 publication-title: J Infect Dis. doi: 10.1093/infdis/jir634 – volume: 5 start-page: CD011801 year: 2016 ident: 2798_CR18 publication-title: Cochrane Database Syst Rev. – volume: 201 start-page: 276 issue: 3 year: 2020 ident: 2798_CR16 publication-title: Am J Respir Crit Care Med. doi: 10.1164/rccm.201904-0903SO – volume: 92 start-page: 541 issue: 3 year: 1998 ident: 2798_CR33 publication-title: Respir Med. doi: 10.1016/S0954-6111(98)90305-5 – volume: 5 start-page: 226 year: 2014 ident: 2798_CR4 publication-title: Front Microbiol. doi: 10.3389/fmicb.2014.00226 – volume: 173 start-page: 544 issue: 6 year: 2019 ident: 2798_CR9 publication-title: JAMA Pediatr. doi: 10.1001/jamapediatrics.2019.0384 – volume: 185 start-page: 744 issue: 6 year: 2002 ident: 2798_CR22 publication-title: J Infect Dis. doi: 10.1086/339298 – volume: 6 start-page: e27898 issue: 11 year: 2011 ident: 2798_CR13 publication-title: PLoS One. doi: 10.1371/journal.pone.0027898 – volume: 115 start-page: 132 issue: 1 year: 2005 ident: 2798_CR25 publication-title: J Allergy Clin Immunol. doi: 10.1016/j.jaci.2004.09.025 – volume: 82 start-page: 1458 issue: 8 year: 2010 ident: 2798_CR36 publication-title: J Med Virol. doi: 10.1002/jmv.21819 – volume: 179 start-page: 19 issue: 1 year: 2009 ident: 2798_CR1 publication-title: Am J Respir Crit Care Med. doi: 10.1164/rccm.200807-1126OC – volume: 148 start-page: 1508 issue: 6 year: 2015 ident: 2798_CR5 publication-title: Chest. doi: 10.1378/chest.15-1335 – volume: 164 start-page: 1392 issue: 8 Pt 1 year: 2001 ident: 2798_CR24 publication-title: Am J Respir Crit Care Med. doi: 10.1164/ajrccm.164.8.2104102 – volume: 69 start-page: 314 issue: 3 year: 2020 ident: 2798_CR19 publication-title: Allergol Int. doi: 10.1016/j.alit.2020.02.005 – volume: 115 start-page: 233 issue: 2 year: 2005 ident: 2798_CR12 publication-title: J Allergy Clin Immunol. doi: 10.1016/j.jaci.2004.11.014 – volume: 138 start-page: 1608 issue: 6 year: 2016 ident: 2798_CR11 publication-title: J Allergy Clin Immunol. doi: 10.1016/j.jaci.2016.09.028 – volume: 9 start-page: 2567 issue: 7 year: 2021 ident: 2798_CR15 publication-title: J Allergy Clin Immunol Pract. doi: 10.1016/j.jaip.2021.03.035 – volume: 154 start-page: 396–400, 400 e3 issue: 3 year: 2009 ident: 2798_CR37 publication-title: J Pediatr. doi: 10.1016/j.jpeds.2008.08.036 – volume: 195 start-page: 854 issue: 7 year: 2017 ident: 2798_CR3 publication-title: Am J Respir Crit Care Med. doi: 10.1164/rccm.201606-1213PP – volume: 16 start-page: 15 issue: 1 year: 1998 ident: 2798_CR34 publication-title: J Emerg Med. doi: 10.1016/S0736-4679(97)00227-8 – volume: 40 start-page: 256 issue: 6 year: 2002 ident: 2798_CR35 publication-title: Int J Clin Pharmacol Ther. doi: 10.5414/CPP40256 – volume: 31 start-page: e2193 issue: 4 year: 2021 ident: 2798_CR2 publication-title: Rev Med Virol. doi: 10.1002/rmv.2193 |
| SSID | ssj0017853 |
| Score | 2.3390505 |
| Snippet | Human rhinoviruses (HRVs) infection is a common cause of exacerbations in pediatric patients with asthma. However, the effects of corticosteroids on... Background Human rhinoviruses (HRVs) infection is a common cause of exacerbations in pediatric patients with asthma. However, the effects of corticosteroids on... BackgroundHuman rhinoviruses (HRVs) infection is a common cause of exacerbations in pediatric patients with asthma. However, the effects of corticosteroids on... Abstract Background Human rhinoviruses (HRVs) infection is a common cause of exacerbations in pediatric patients with asthma. However, the effects of... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 487 |
| SubjectTerms | Administration, Inhalation Adrenal Cortex Hormones Analysis Anti-Asthmatic Agents - therapeutic use Asthma Asthma - chemically induced Asthma - drug therapy Asthma in children Child Children Clinical outcomes Corticosteroids Exacerbation Health aspects Hospital patients Hospitals Human rhinovirus Humans Infection Infections Influenza Inpatients Laboratories Medical research Medicine, Experimental Observational studies Pathogens Patients Pediatric asthma Pediatrics Pulmonary function tests Pulmonology Respiratory function Respiratory syncytial virus Rhinovirus Steroids Viral infections Viruses |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9UwDI_QDogLYnyWjSlISBxQtKZN3YTbmJgmJDgxabcoSRO9Hmin1_fQ_hH-3znph17FgQvHNo6axHZtJ87PhHyociOEUJxJDjkT3gMzpXcsIqVHeYYQEtrnD7i-Ed9uq9uDUl8xJ2yEBx4X7tw7aJQvFK-CFSI30uNny1CgnWy8MAlsG23eHExN5wc1WqH5ioyE84HH8zSG9imeWSrJYGWGElr_3__kA6O0Tpg8sEBXz8jTyXWkF-OQj8kj3z0nj79Ph-MvyJ8RiXigfaBL_jiNG60UQ0zsFO9zbPu2QYqOpuJ8dLtpu_53u90PDINzZHNDzbDb_DLU3xuHSz5u6NG2o3dzUQ98mNBYh8_UUJzHfF2T9nbZ5MWRJujal-Tm6uvPy2s2VV1gDn2bHXMecqMaIYXjYC3yGHyuPDeFgdzJILj3xlpAs1bmoSyCCi4A55Y3yJGqLl-Ro67v_BtCDcbeqjZgCqdEbpUMzihh0YmJKDsyZOTTzAR9N4Jr6BSUSNAjyzQS6sQyDRn5Evm0UEZg7PQCxUVP4qL_JS4Z-Ri5rKP6IiudmW4h4IAjEJa-qOsImVaWIiOnK0pUO7dunuVET2o_6EKhy8QBpMrI-6U59oypbJ3v90gTC3ZilFfzjLwexWqZUinxn5iDzIhcCdxqzuuWrt0kUHAM7RWgO_f2f6zSCXlSRGWJaTvVKTnabff-HTpfO3uW9OwBOqYxrA priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgiftvzlAiCDxKuadM08UVO8TgEffJg30KaJm4frl3bXfEfuf_XmfTDK4KPu5nuTjozmcxk8htC3hSpFUJozhSXKRPeS2Zz7xgipaM-yxAi2uc3eXEpvmyKzZRwG6ayynlNjAt13TnMkZ9mGrwRl1LpD7ufDLtG4enq1ELjNrmD0GWo1eVmCbiw8Xw-X5RR8nTgeKrGwEvhyaVWTK6cUcTs_3dlvuGa1mWTN_zQ-QNyf9pA0rNR4g_JLd8-Ine_Tkfkj8n1iEc80C7QpYqcYrqVQqAJD-Gtjr5raqBoaWzRR_tt03a_mv4wMAjRQdg1tcN-e2Wp_20dvPgxrUeblu7m1h7wYcJkHd5TS2Ee86VN2lVLqhc4jQC2T8jl-efvny7Y1HuBOdjh7JnzMrW6Fko4LqsKJC19qj23mZWpU0Fw721VSXBueRryLOjgguS84nVR-6LMn5Kjtmv9c0ItROC6tNJmTou00io4q0UFWxnE2lEhIe9mIZjdCLFhYmiipBlFZoDQRJEZmZCPKKeFEuGx4xdd_8NM1maA21r7TPMiVEKkVnnQ1TzA3wFzwsKPvEUpGzRiEKWz010EYBjhsMxZWSJwWp6LhJysKMH43Hp41hMzGf9g_qpqQl4vw_gkFrS1vjsADbbthFiv5Al5NqrVMqVcwcqYSpUQtVK41ZzXI22zjdDgEOBrCZu64__z9YLcy9AMsCynOCFH-_7gX8Lmal-9ihb0B9puJ_I priority: 102 providerName: ProQuest |
| Title | Effects of treatment with corticosteroids on human rhinovirus-induced asthma exacerbations in pediatric inpatients: a prospective observational study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38053068 https://www.proquest.com/docview/2902116689 https://www.proquest.com/docview/2898957671 https://pubmed.ncbi.nlm.nih.gov/PMC10696820 https://doaj.org/article/ec6d9e2915fb440a8eebe3f2355de4a6 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bi9QwFA57AfFFvFtdhwiCDxJt2jRNBJEd2WURdpHFgcGXkKbJzoC2azsj6w_x_3qSXtziPvhSmCZtkznfyTknl-8g9DKLNWNMUiIojwmzlhOdWkM8U7rHM3cusH2e8ZMF-7TMljtoSHfU_4HtjaGdzye1aL69ufrx6wMo_Pug8IK_balfLSNgffyKpBSE76J9sEy5z2hwyv6uKuQisFJSGJBJwjgfDtHc-I6JoQp8_v-O2tfM1nRL5TUbdXwX3emdS3zYoeEe2rHVfXTrtF8-f4B-d1zFLa4dHneYYz8ViyEIhYf8iY-mXpdQo8IhfR9uVuuq_rluti2B8B2AUGLdblbfNbZX2oBQuik_vK7w5ZD2A370fK3tO6wx9GM40InrYpwGhpYGctuHaHF89OXjCenzMhAD3s-GGMtjLUsmmKG8KAAF3MbSUp1oHhvhGLVWFwUHw5fGLk2cdMZxSgtaZqXN8vQR2qvqyj5BWEN0LnPNdWIkiwspnNGSFeDmeB4e4SL0ehCCuuzoN1QIWwRXncgUVFRBZIpHaO7lNNb01NnhRt1cqF4TFbS2lDaRNHMFY7EWFnCcOvgcNI5peMkrL2XlIQeiNLo_pwAN9lRZ6jDPPalamrIIHUxqgmKaafGAEzXgWiUSnCrKuZARejEW-yf9ZrfK1luo41N6QhyY0wg97mA1dikVMGrGXERITAA36fO0pFqvAm04BP-Sg8P39D8-_AzdTrwu-H072QHa2zRb-xy8r00xQ7v5Mp-h_fnR2efzWZjDmAU1g-v5_OsfGFwzoA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4k2ggJFAHFDUOHEcGwmh8qi29HFqpb0Zx7HZHEiWzS6PH8Lf4DcykxeNkLj1uPEkO9a8PLbnG0KepZHhnCsWSiaikDsnQpM4GyJSOuqz8L5F-zwRszP-cZ7Ot8jvoRYGr1UOPrF11EVtcY98N1YQjZgQUr1Zfg2xaxSerg4tNDq1OHQ_v0PK1rw-eA_yfR7H-x9O383CvqtAaCF2r0PrRGRUwSW3TOQ5zEG4SDlmYiMiKz1nzpk8F-C2k8gnsVfeesFYzoq0cGmWwHcvkcsQeCNM9rL5mOBho_tkKMyRYrdheIoXQlTEk1IlQzEJfm2PgH8jwblQOL2meS7u7d8g1_sFK93rNOwm2XLVLXLluD-Sv01-dfjHDa09HW-tU9zepZDYwktYRbKqywIoKtq2BKSrRVnV38rVpgnLqgDlKqhp1osvhrofxoKgu21EWlZ0ObQSgR89BmzzihoK8xiKRGmdj1vLwGkLmHuHnF2IVO6S7aqu3H1CDWT8KjPCxFbxKFfSW6N4DksnxPaRPiAvByHoZQfpodtUSArdiUwDoW5FpkVA3qKcRkqE424f1KvPurduDdwWysWKpT7nPDLSgW0kHv4OmOMGPvICpazRaYAorelrH4BhhN_Se1mGQG1JwgOyM6EEY7fT4UFPdO9sGv3XNALydBzGN_ECXeXqDdBgm1DILTMWkHudWo1TSiR44kjIgMiJwk3mPB2pykULRc4iBFeKowf_5-sJuTo7PT7SRwcnhw_JtRhNAq8EpTtke73auEewsFvnj1trouTTRZvvH93HZrs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+treatment+with+corticosteroids+on+human+rhinovirus-induced+asthma+exacerbations+in+pediatric+inpatients%3A+a+prospective+observational+study&rft.jtitle=BMC+pulmonary+medicine&rft.au=Kan-O%2C+Keiko&rft.au=Washio%2C+Yasuyoshi&rft.au=Oki%2C+Takeshi&rft.au=Fujimoto%2C+Tsuguto&rft.date=2023-12-05&rft.issn=1471-2466&rft.eissn=1471-2466&rft.volume=23&rft.issue=1&rft.spage=487&rft_id=info:doi/10.1186%2Fs12890-023-02798-6&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2466&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2466&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2466&client=summon |